Mindray Medical International Limited
The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Mindray Medical International Limited beat expectations on revenues and met expectations on earnings per share.
Compared to the prior-year quarter, revenue improved significantly and GAAP earnings per share grew.
Margins dropped across the board.
Mindray Medical International Limited logged revenue of $264.1 million. The eight analysts polled by S&P Capital IQ expected revenue of $248.1 million on the same basis. GAAP reported sales were 25% higher than the prior-year quarter's $211.0 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Non-GAAP EPS came in at $0.44. The eight earnings estimates compiled by S&P Capital IQ predicted $0.44 per share on the same basis. GAAP EPS of $0.40 for Q4 were 14% higher than the prior-year quarter's $0.35 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 54.2%, 50 basis points worse than the prior-year quarter. Operating margin was 18.1%, 10 basis points worse than the prior-year quarter. Net margin was 17.7%, 180 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $210.6 million. On the bottom line, the average EPS estimate is $0.37.
Next year's average estimate for revenue is $1.03 billion. The average EPS estimate is $1.76.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 1,380 members out of 1,414 rating the stock outperform, and 34 members rating it underperform. Among 359 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 346 give Mindray Medical International Limited a green thumbs-up, and 13 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Mindray Medical International Limited is outperform, with an average price target of $30.75.
The healthcare investing landscape is littered with also-rans and a few major winners. Is Mindray Medical International Limited performing well enough for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will deliver amazing returns during the next few years. Click here for instant access to this free report.
- Add Mindray Medical International Limited to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Will Mindray Medical International Beat These Analyst Estimates?
Will Mindray Medical International Fall Short Next Quarter?
Look here for a clue.
Why Mindray Medical International's Earnings May Be Less Than Awesome
Don't just count the cash, time it.